NCT01504165 - Pharmacokinetics in Subjects With Renal Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Renal Impairment

Interventions

DRUG

cilengitide 2000mg

A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1

DRUG

cilengitide 2000mg

A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1

DRUG

cilengitide 2000mg

A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1

DRUG

cilengitide 1000mg

A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1

DRUG

cilengitide > 1000mg and up to 2000mg

A single dose of cilengitide \> 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision

Trial Locations (2)

Unknown

For Research Sites contact Merck KGaA Communication Center in, Darmstadt

CRS Clincial Research Services Kiel GmbH, Kiel

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY